{"id":"administration-of-daa-based-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL324631","moleculeType":"Small molecule","molecularWeight":"643.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Direct-acting antivirals (DAAs) target specific HCV enzymes (protease, polymerase, NS5A) required for viral replication. By inhibiting these viral proteins, DAAs prevent HCV from reproducing and allow the immune system to clear the infection, achieving sustained virologic response (SVR) and functional cure in the majority of treated patients.","oneSentence":"DAA-based treatment directly inhibits hepatitis C virus (HCV) nonstructural proteins to block viral replication and cure chronic HCV infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:52.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes"}]},"trialDetails":[{"nctId":"NCT03949764","phase":"PHASE4","title":"The Kentucky Viral Hepatitis Treatment Study","status":"COMPLETED","sponsor":"Jennifer Havens","startDate":"2019-09-23","conditions":"Hepatitis C, Opioid-Related Disorders, Injection Drug Use","enrollment":374},{"nctId":"NCT07098481","phase":"PHASE4","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-09-01","conditions":"Hepatitis C Virus Infection","enrollment":576},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT06349902","phase":"","title":"Re-link HCV in Substance-Use Telemedicine Program","status":"RECRUITING","sponsor":"trueNorth Medical Centres","startDate":"2024-03-12","conditions":"Hepatitis C","enrollment":5000},{"nctId":"NCT04513899","phase":"NA","title":"Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-10-05","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":10},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT04008927","phase":"NA","title":"A Community-based Intervention Among Active Drug Users in Montpellier","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-18","conditions":"Drug Use, HCV Infection","enrollment":554},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64},{"nctId":"NCT02102451","phase":"","title":"Control and Elimination Within Australia of Hepatitis C From People Living With HIV","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2014-07","conditions":"Hepatitis C, HIV, HIV-HCV Coinfection","enrollment":492},{"nctId":"NCT02723084","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-08","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":136},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03707080","phase":"","title":"Direct Acting Antiviral-Post Authorization Safety Study","status":"COMPLETED","sponsor":"Target PharmaSolutions, Inc.","startDate":"2018-03-09","conditions":"Hepatitis C, Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT02533934","phase":"PHASE4","title":"Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"HIV, Hepatitis C, Cirrhosis","enrollment":68},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT02156570","phase":"PHASE4","title":"DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2014-10","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT01974687","phase":"PHASE1, PHASE2","title":"Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-31","conditions":"Chronic Hepatitis C","enrollment":178},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT03551444","phase":"PHASE3","title":"Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-10-01","conditions":"Hepatocellular Carcinoma, Hepatitis C, Chronic","enrollment":80},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02555475","phase":"NA","title":"The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital","status":"COMPLETED","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2016-03","conditions":"Hepatitis C","enrollment":140},{"nctId":"NCT02605304","phase":"PHASE2","title":"12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2016-02-17","conditions":"HIV-1 Infection, Hepatitis C","enrollment":7},{"nctId":"NCT02442271","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-27","conditions":"Chronic Hepatitis C Infection","enrollment":222},{"nctId":"NCT02399345","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":"Chronic Hepatitis C Virus (HCV Infection Genotype 1)","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Administration of DAA-based treatment","genericName":"Administration of DAA-based treatment","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAA-based treatment directly inhibits hepatitis C virus (HCV) nonstructural proteins to block viral replication and cure chronic HCV infection. Used for Chronic hepatitis C virus (HCV) infection, all genotypes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}